This chart describes the different types of insulin and how they can affect you. Within each category, there are different formulations that may vary the onset, peak, or duration.

Insulin glargine is a basal insulin ... While that is well below its peak of around $7 billion a year before biosimilars launched, the US has remained a stronghold for the brand because the ...

Insulin lispro has a very rapid action, with a peak 1 h after subcutaneous injection ... use in pregnancy are available. [53] Insulin Glargine. The first long-acting insulin analogue was approved ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Lantus was a $6.5 billion product at its peak but started to decline in 2014 after the first biosimilars were approved in Europe, and as downward pressure on insulin prices in the US started to ...